Martha H. Marsh - Apr 28, 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Apr 28, 2022
Transactions value $
-$2,358,128
Form type
4
Date filed
4/28/2022, 09:02 PM
Previous filing
Apr 22, 2022
Next filing
May 5, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $746K +28.7K +107.26% $25.99 55.5K Apr 28, 2022 Direct
transaction EW Common Stock Sale -$3.1M -28.7K -51.75% $108.09 26.8K Apr 28, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Director Stock Option (Right to Acquire) Options Exercise $0 -28.7K -100% $0.00* 0 Apr 28, 2022 Common Stock 28.7K $25.99 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $108.00 to $108.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

On May 29, 2020, the common stock of the Issuer split 3-for-1, resulting in the Reporting Person's ownership of additional shares of common stock and stock options. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.